Gabexate mesilate suppresses influenza pneumonia in mice through inhibition of cytokines

Journal of International Medical Research

Volumn 36, Issue 2, 2008, Pages 322-328

  Kosai, K ^a   Seki, Masafumi ^a   Yanagihara, K ^a   Nakamura, S ^a   Kurihara, S ^a   Izumikawa, K ^a   Kakeya, H ^a   Yamamoto, Y ^a   Tashiro, T ^a   Kohno, S ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Cytokines; Gabexate mesilate; Influenza virus

Indexed keywords

CHEMOKINE; CYTOKINE; GABEXATE MESILATE; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; INFLUENZA VIRUS A; INHIBITION KINETICS; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS PNEUMONIA;

EID: 42049084815     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600215     Document Type: Article

References (20)

1. Murphy BR, Webster R: Orthomyxoviruses. In: Fields Virology (Fields BN, Knipe DM, Howley PM, et al, eds), 3rd edn. Philadelphia: Raven Press, 1996; pp 1397-1445.
2. Glezen WP, Greenberg S, Atmor RL, et al: Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000; 283: 499-505.
3. Potter CW: Influenza. In: Principles and Practice of Clinical Virology (Zuckerman AJ, Banatvala J, Pattison JR, et al, eds), 5th edn. Chichester: John Wiley, 2004, pp 271-297.
4. Mandell LA, Wunderink RG, Anzueto A, et al: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in odults. Clin Infect Dis 2007; 44: S27-S72.
5. Woodhead M, Blasi F, Ewig S, et al: Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005, 26: 1138-1180.
6. Kido H, Okumura Y, Yomada H, et al: Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des 2007; 13: 403-412.
7. Kido H, Yokogoshi Y, Sakai K, et al: Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992; 267: 13573-13579.
8. Tashiro M, Yokogoshi Y, Tobita. K, et al: Tryptase Clara, an activating protease for Sendai virus in rat lungs, is involved in pneumopathogenicity. J Virol 1992; 66: 7211-7216.
9. White MR, Crouch E, Vesona J, et al: Respiratory innate immune proteins differentially modulate the neutrophil respiratory burst response to influenza A virus. Am J Physiol Lung Cell Mol Physiol 2005; 289: L606-L616.
10. White MR, Crouch E, van Eijk M, et al: Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor. Am J Physiol Lung Cell Mol Physiol 2005, 288: L831-L840.
11. Seki M, Yanagihara K, Higashiyama Y, et al: Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 2004; 24: 143-149.
12. Seki M, Higashiyama Y, Tomono K, et al: Acute infection with influenza virus enhances susceptibility to fatal pneumonia following Streptococcus pneumoniae infection in mice with chronic pulmonary colonization with Pseudomonas aeruginosa. Clin Exp Immunol 2004; 137: 35-40.
13. Takahashi H, Funahashi H, Sawai H, et al: Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-κB activation and increases TNF-α-mediated opoptosis in human pancreatic cancer cells. Dig Dis Sci 2007; 52: 2646-2652.
14. Inoue S, Sugitani A, Yamamoto H, et al: Effect of synthetic protease inhibitor gabexate mesilate on the attenuation of ischemia/ reperfusion injury in canine kidney autotransplantation. Surgery 2005; 137: 216-224.
15. Harado H, Miyake H, Ochi K, et al: Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991, 9: 75-79.
16. Hsu JT, Chen H, Chiu DF, et al: Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med Assoc 2004; 103: 678-684.
17. Luh SP, Tsai C, Shau WY, et al: Protective effects of inhaled nitric oxide and gabexate mesilate in lung reperfusion injury after transplantation from non-heart-beat donors. J Heart Lung Transplant 2002; 21: 251-259.
18. Harada N, Okajimo. K, Kushimoto S: Gobexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 1999; 27: 1958-1964.
19. Chen CC, Wang S, Tsay SH, et al: Effects of gabexate mesilate on serum inflammatory cytokines in rats with acute necrotizing pancreatitis. Cytokine 2006; 33: 95-99.
20. Manes G, Ardizzone S, Lombardi G, et al: Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007; 65: 982-987.